Amryt Pharma plc is a commercial-stage biopharmaceutical company committed to enhancing the lives of individuals with rare and orphan diseases. The firm achieves this by acquiring, developing, and bringing to market specialized therapies. Among its current offerings, Amryt provides: Metreleptin, prescribed as a dietary adjunct and replacement therapy, addresses complications arising from leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Oral octreotide serves as a long-term maintenance solution for those with acromegaly. Lomitapide, used in conjunction with a low-fat diet and other lipid-lowering medications, aids adults diagnosed with Homozygous familial Hypercholesteraemia. Its pipeline features promising investigational therapies, including Oleogel-S10, which targets the skin manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB)—a severe and uncommon genetic skin disorder impacting both children and adults. Additionally, AP103 is a pre-clinical gene therapy under development for dystrophic EB. Amryt's products are distributed across the Americas, Europe, and the Middle East. Established in 2015, Amryt Pharma plc maintains its headquarters in Dublin, Ireland.